End-of-day quote
Colombo S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
50.7
LKR
|
0.00%
|
|
+1.20%
|
-1.93%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
973.6
|
901.1
|
1,021
|
1,084
|
1,235
|
1,280
|
Enterprise Value (EV)
1 |
957.7
|
1,069
|
1,013
|
1,220
|
1,075
|
986.5
|
P/E ratio
|
3.71
x
|
3.68
x
|
5.54
x
|
-3.55
x
|
37.9
x
|
14.9
x
|
Yield
|
1.96%
|
4.24%
|
-
|
5.87%
|
-
|
-
|
Capitalization / Revenue
|
8.48
x
|
54.4
x
|
16.7
x
|
19.4
x
|
32.1
x
|
14.5
x
|
EV / Revenue
|
8.34
x
|
64.6
x
|
16.6
x
|
21.8
x
|
27.9
x
|
11.2
x
|
EV / EBITDA
|
68.1
x
|
-123
x
|
38.8
x
|
85.3
x
|
-294
x
|
24
x
|
EV / FCF
|
1.52
x
|
-17.7
x
|
6.4
x
|
-1.76
x
|
4.29
x
|
21.7
x
|
FCF Yield
|
65.8%
|
-5.64%
|
15.6%
|
-56.8%
|
23.3%
|
4.6%
|
Price to Book
|
0.52
x
|
0.43
x
|
0.45
x
|
0.57
x
|
0.64
x
|
0.63
x
|
Nbr of stocks (in thousands)
|
25,457
|
25,457
|
25,457
|
25,457
|
25,457
|
25,457
|
Reference price
2 |
38.24
|
35.40
|
40.11
|
42.59
|
48.50
|
50.30
|
Announcement Date
|
18-08-31
|
19-09-03
|
20-11-05
|
21-08-31
|
22-08-31
|
23-08-28
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
114.9
|
16.55
|
61.05
|
56.02
|
38.47
|
88.21
|
EBITDA
1 |
14.07
|
-8.701
|
26.12
|
14.31
|
-3.652
|
41.16
|
EBIT
1 |
14.01
|
-8.825
|
25.42
|
13.57
|
-4.806
|
40.42
|
Operating Margin
|
12.19%
|
-53.32%
|
41.64%
|
24.21%
|
-12.49%
|
45.82%
|
Earnings before Tax (EBT)
1 |
287
|
222.1
|
230.3
|
-309
|
57.43
|
222.2
|
Net income
1 |
262.4
|
244.6
|
184.9
|
-305.7
|
32.61
|
86.08
|
Net margin
|
228.39%
|
1,478.18%
|
302.82%
|
-545.64%
|
84.79%
|
97.59%
|
EPS
2 |
10.31
|
9.610
|
7.245
|
-12.01
|
1.281
|
3.373
|
Free Cash Flow
1 |
630.5
|
-60.23
|
158.4
|
-693.1
|
250.8
|
45.39
|
FCF margin
|
548.83%
|
-363.95%
|
259.48%
|
-1,237.17%
|
652.06%
|
51.46%
|
FCF Conversion (EBITDA)
|
4,482.29%
|
-
|
606.55%
|
-
|
-
|
110.28%
|
FCF Conversion (Net income)
|
240.31%
|
-
|
85.69%
|
-
|
769.06%
|
52.73%
|
Dividend per Share
2 |
0.7500
|
1.500
|
-
|
2.500
|
-
|
-
|
Announcement Date
|
18-08-31
|
19-09-03
|
20-11-05
|
21-08-31
|
22-08-31
|
23-08-28
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
168
|
-
|
136
|
-
|
-
|
Net Cash position
1 |
15.9
|
-
|
7.77
|
-
|
160
|
294
|
Leverage (Debt/EBITDA)
|
-
|
-19.25
x
|
-
|
9.53
x
|
-
|
-
|
Free Cash Flow
1 |
630
|
-60.2
|
158
|
-693
|
251
|
45.4
|
ROE (net income / shareholders' equity)
|
14.9%
|
12.3%
|
8.48%
|
-14.6%
|
1.7%
|
4.35%
|
ROA (Net income/ Total Assets)
|
0.49%
|
-0.26%
|
0.67%
|
0.38%
|
-0.15%
|
1.16%
|
Assets
1 |
53,885
|
-95,414
|
27,528
|
-80,360
|
-22,385
|
7,390
|
Book Value Per Share
2 |
73.90
|
82.00
|
89.30
|
74.70
|
76.00
|
79.40
|
Cash Flow per Share
2 |
0.6300
|
1.540
|
0.4300
|
0.8100
|
1.370
|
0.3700
|
Capex
1 |
0.09
|
0.01
|
0.81
|
1.12
|
0.06
|
0.12
|
Capex / Sales
|
0.08%
|
0.08%
|
1.32%
|
1.99%
|
0.15%
|
0.14%
|
Announcement Date
|
18-08-31
|
19-09-03
|
20-11-05
|
21-08-31
|
22-08-31
|
23-08-28
|
|
1st Jan change
|
Capi.
|
---|
| -1.93% | 4.27M | | -29.72% | 15.43B | | -21.99% | 12.31B | | -23.82% | 6.59B | | +12.34% | 6.3B | | -6.99% | 5.88B | | -1.17% | 4.74B | | +60.03% | 4.7B | | -5.50% | 4.03B | | -8.59% | 3.58B |
Other Drug Retailers
|